BRIEF-Summit's IND cleared by FDA

* Summit's IND cleared by FDA allowing expansion of phaseout

dmd, a phase 2 clinical trial of ezutromid (smt c1100), into the

us

Source text for Eikon:

Further company coverage:

(Bengaluru...

Read more